REPL vs RGNX

Replimune Group, Inc. vs REGENXBIO Inc. — Valuation Comparison 2026

REPL

Biotechnology
Replimune Group, Inc.
Quality
4.4
out of 10
Value Trap
18
SAFE
Price
$4.68
Last close
Models
7/13
Active
VS

RGNX

Biotechnology
REGENXBIO Inc.
Quality
6.4
out of 10
Value Trap
18
SAFE
Price
$6.89
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType REPL Fair ValueREPL Upside RGNX Fair ValueRGNX Upside
Bayesian DCF Intrinsic $1.65 -64.7% $0.88 -87.3%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $2.21 -52.7% $0.23 -97.4%
Dynamic NAV Asset-Based $3.58 -23.4% $1.93 -72.0%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for REPL vs RGNX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

REPL vs RGNX — Which Stock Is More Undervalued?

RGNX scores higher with a 6.4/10 quality rating vs REPL's 4.4/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Replimune Group, Inc. (REPL) and REGENXBIO Inc. (RGNX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

REPL currently trades at $4.68 with a QOC of 4.4/10, while RGNX trades at $6.89 with a QOC of 6.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).